GALDY — Galderma Group AG/ADR

OTC · Unknown · Unknown · CIK 2021390 ·
Last close
$43.28
Market Cap
$50.46B
52W High
$46.31
52W Low
$38.69
ADV30
93,983
Next earnings
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 13,393,000,000 780,000,000 5,244,000,000
Jun 2025 12,877,000,000 458,000,000 5,147,000,000
Dec 2024 12,617,000,000 457,000,000 4,827,000,000

Balance + Analyst (yfinance extras)

Retained Earnings
$6,347,000,000
Inventory
$525,000,000
Receivables
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,922,999,808
EBITDA
$1,386,000,000
Free Cash Flow
$874,625,024
Enterprise Value
$52,362,403,840
Total Cash
$839,000,000
Total Debt
$2,716,000,000
Shares Out
1,165,944,685
Trailing EPS
$0.73
Book Value
$7.05
ROE
10.8%
ROA
5.4%
Div Yield
0.20%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 5,241,000,000 876,000,000 613,000,000 13,393,000,000 5,244,000,000 1,185,000,000
Dec 2024 4,440,000,000 678,000,000 231,000,000 12,617,000,000 4,827,000,000 488,000,000
Dec 2023 4,117,000,000 611,000,000 -57,000,000 12,471,000,000 7,102,000,000 165,000,000
Dec 2022 3,823,900,000 406,000,000 -98,500,000 111,300,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$6.32

Peers — same industry

TickerNameMarket CapLastDaily %
CTVA Corteva, Inc. $50.39B $75.53
ROK ROCKWELL AUTOMATION, INC $50.13B $451.39
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP $49.92B $295.54
NKE NIKE, Inc. $48.70B $40.51
RKLB Rocket Lab Corp $48.57B $81.17

News headlines (Yahoo Finance, 1h cache)

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
2026-08-11 05:00 · Yahoo
Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook
2026-07-30 13:29 · Yahoo
Galderma Group AG (GDERF) Half Year 2026 Earnings Call Highlights: Record Sales and Strategic ...
2026-07-23 19:00 · Yahoo
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
2026-07-23 05:00 · Yahoo
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
2026-07-20 05:00 · Yahoo
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
2026-07-07 05:00 · Yahoo
Galderma falls after FDA issues second setback for Botox rival
2026-07-01 08:08 · Yahoo
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
2026-07-01 05:00 · Yahoo
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
2026-06-16 13:40 · Yahoo
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
2026-06-11 05:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.